MNPR
Monopar Therapeutics Inc.
$107.72
-2.85%
2026-08-21
About Monopar Therapeutics Inc.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Key Fundamentals
Forward P/E
-57.09
EPS (TTM)
$-2.20
ROE
-19.5%
Profit Margin
0.0%
Debt/Equity
0.16
Price/Book
5.80
Beta
1.51
Market Cap
$758.7M
Avg Volume (10D)
257K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$124.82
60D Low
$57.70
Avg Volume
218K
Latest Close
$107.72
Get breakout alerts for MNPR
Sign up for Breakout Scanner to receive daily notifications when MNPR triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
Monopar Therapeutics Inc. (MNPR) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors MNPR daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. MNPR operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.